Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests
Authors' conclusion
Careful monitoring without additional medications is recommended at first in acromegaly patients with normal IGF-1 and high GH levels considering the possibility of recurrence in the future.
Study context
- Population
- Acromegaly patients after initial surgery with 75-g oral glucose tolerance test (OGTT) 3 months postoperatively; high-GH group: normal IGF-1 and nadir GH ≥0.4 µg/L on OGTT23 in high-GH group
- Participants
- 110 patients
- Exposure
- Late-remission type vs Recurrence type vs Persistent type
- Late-remission typen = 10
- Recurrence typen = 5
- Persistent typen = 8
- Outcome
- Proportion with normal IGF-1 and high GH (high-GH group) and its subtypes
- Follow-up
- 3 months postoperatively
Main finding
As reported in the abstract
Late-remission type
10
events
Recurrence type
5
events
Persistent type
8
events
- Proportion of patients in high-GH group
- 23.6%
Observational data: associations, not effects.
Further findings
Sex in late-remission type
- Significantly more women than men in late-remission type
- P = 0.0178
Tumour size and preoperative GH, persistent type vs complete remission at 3 months
- Larger tumors in persistent type
- P = 0.0110
- Higher preoperative GH in persistent type
- P = 0.0018
Original publication
Management policy for postoperative acromegaly patients with normal IGF-1 and high GH levels on oral glucose tests. Pituitary. Published 26 December 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →